Health · Pharma & Biotech · 1 hr ago

Experimental weight-loss drug led to average 17.7% loss in 48-week trial

Experimental weight-loss drug led to average 17.7% loss in 48-week trial

A weekly experimental injection called ribupatide helped adults with overweight or obesity lose weight in a trial led by researchers from Fudan University in Shanghai.

The study included 567 people, who received one of three doses of the drug or a dummy injection.

After 48 weeks, participants on the highest dose had lost an average of 17.7% of their starting weight, compared with 1.4% among those given the dummy treatment.

Ribupatide works by mimicking two hormones that help regulate appetite and blood sugar, in a way similar to Mounjaro.

The trial found that weight loss had not clearly levelled off among people on the two highest doses when it ended.

Nausea, vomiting and diarrhoea were common, affecting about half of those on the lowest dose and about two-thirds on the highest, though most cases were mild or moderate.

The results suggest ribupatide could become a rival to existing weight-loss injections, but it has not been directly compared with Wegovy or Mounjaro.

Phase three trials of the drug have begun recruiting patients in Britain.

1 source

Related

What people are saying

ResearchersStudy authors
Reductions in body weight at week 48 were 16.4 per cent and 17.7 per cent with ribupatide 4mg and 6mg, respectively, and weight loss had not clearly plateaued in either group
via Daily Mail